12:00 AM
 | 
Aug 08, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

HP802-247: Phase IIb data

DFB's Healthpoint Biotherapeutics subsidiary reported data from a double-blind, U.S. Phase IIb trial in 228 patients ages 18 and older with venous leg ulcers of at least 6 weeks in duration, but not more than 24 months, showing that HP802-247 plus standard of care (SOC) met the primary endpoint of significantly improving the average percent change in target wound area from baseline to week 12 vs. placebo plus SOC (p=0.04). HP802-247 plus SOC also met the...

Read the full 357 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >